Last reviewed · How we verify
split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose
split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose is a Biologic drug developed by Sinovac Biotech Co., Ltd. It is currently FDA-approved.
Sinovac Biotech's split-virion, adjuvanted H1N1 vaccine, containing 7.5 μg per dose, is currently marketed. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports market stability. The primary risk lies in the competitive landscape, which could intensify as the patent approaches expiration.
At a glance
| Generic name | split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose CI brief — competitive landscape report
- split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI